Temferon
Gene therapy / editing
Evidence outlook
Development stopped: Phase 1/2 study terminated
The drug's registered studies are all terminated, withdrawn or suspended (NCT03875495: terminated); none completed, so no evidence signal is assigned. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
TEM-GBM NCT03866109 · Glioblastoma Registry: NCT03866109 | 1/2 | Tolerability and safety of Temferon over the first 90 days following administration as determined by the incidence of adverse events 2026-05-27 | Primary safety endpoint: no dose-limiting toxicities up to the highest Temferon dose tested. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Glioblastoma: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Temferon: this drug | Phase 1/2 | Gene therapy / editing | Interferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cells | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Temozolomide | Approved | Small molecule | DNA alkylation (O6-guanine) | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Phase 3 | Small molecule | PARP1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| TNG456 | Phase 1/2 | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication | |
| Zedoresertib | Phase 1/2 | Small molecule | WEE1 kinase | not yet graded | No reviewed efficacy summary in this indication | |
| AZD1390 | Phase 1 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ralometostat | Discontinued | Small molecule | PRMT5 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.